Menicon Launches "Seares®" Ophthalmic Field-of-View Securing Material

Q: What are the key facts in this article?

Menicon will begin sales of "Seares®," an ophthalmic field-of-view securing material developed using self-assembling peptide gel technology, on May 18, 2026. This medical device assists in securing visibility during glaucoma incisional surgery by suppressing blood inflow to the surgical site, thereby reducing surgeon burden and improving surgical maneuverability.

Q: What is the direct answer?

Menicon will begin sales of "Seares®," an ophthalmic field-of-view securing material developed using self-assembling peptide gel technology, on May 18, 2026. This medical device assists in securing visibility during glaucoma incisional surgery by suppressing blood inflow to the surgical site, thereby reducing surgeon burden and improving surgical maneuverability.

Q: What is the source and date?

Source: https://prtimes.jp/main/html/rd/p/000000428.000005623.html | Date: Date unavailable

Information for the Press We provide information about Menicon Group companies and related information to domestic press representatives. Please note that this information is not intended for the general public. Menicon Co., Ltd. (Headquarters: 3-21-19 Aoi, Naka-ku, Nagoya; Director and Representative Executive Officer CEO: Yasutsugu Kawaura) announces that it will begin sales of "Seares®," an ophthalmic field-of-view securing material developed using self-assembling peptide gel technology, on May 18, 2026. "Seares®" is a medical device that suppresses blood inflow to the surgical site during glaucoma incisional surgery and assists in securing visibility. Please refer to the following release for information regarding the medical device approval of this product: https://www.menicon.co.jp/company/news/vol1108.html Treatment for glaucoma*1 includes medication, laser therapy, and surgery. If sufficient effects are not obtained with medication or laser therapy, surgery may be chosen. In recent years, some patients undergoing surgery may experience conjunctival hyperemia as a side effect of long-term medication. In such cases, during glaucoma incisional surgery, heavy bleeding during the operation may make it difficult to see the surgical site. In actual surgery, doctors may repeatedly perform procedures such as wiping away blood, aspirating it, or washing it away with physiological saline, which can make the surgery proceed with difficulty. This can place a significant burden on the surgeon. To broadly address these medical challenges, the Department of Systems Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, and Menicon Co., Ltd. have been working on the development of self-assembling peptide (SPG-178)*2 for some time. Furthermore, the Department of Neurosurgery and Sensory Organ Surgery (Ophthalmology), Graduate School of Medicine, Osaka University, and our company focused on the characteristic of this peptide (SPG-17

Menicon Launches "Seares®" Ophthalmic Field-of-View Securing Material

AI Summary (NQ-processed)

AI Analysis